These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37078252)

  • 1. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
    Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
    Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
    Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
    Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    bioRxiv; 2024 Mar; ():. PubMed ID: 38464204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
    Negi A; Voisin-Chiret AS
    Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
    He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
    Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
    Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL.
    Nayak D; Lv D; Yuan Y; Zhang P; Hu W; Nayak A; Ruben EA; Lv Z; Sung P; Hromas R; Zheng G; Zhou D; Olsen SK
    Nat Commun; 2024 Mar; 15(1):2743. PubMed ID: 38548768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective BCL-X
    Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
    Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PROTAC selectively degrading Bcl-x
    Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
    Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
    Kuusanmäki H; Dufva O; Vähä-Koskela M; Leppä AM; Huuhtanen J; Vänttinen I; Nygren P; Klievink J; Bouhlal J; Pölönen P; Zhang Q; Adnan-Awad S; Mancebo-Pérez C; Saad J; Miettinen J; Javarappa KK; Aakko S; Ruokoranta T; Eldfors S; Heinäniemi M; Theilgaard-Mönch K; Wartiovaara-Kautto U; Keränen M; Porkka K; Konopleva M; Wennerberg K; Kontro M; Heckman CA; Mustjoki S
    Blood; 2023 Mar; 141(13):1610-1625. PubMed ID: 36508699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
    Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
    Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
    Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
    Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
    He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
    Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.
    Lin KH; Winter PS; Xie A; Roth C; Martz CA; Stein EM; Anderson GR; Tingley JP; Wood KC
    Sci Rep; 2016 Jun; 6():27696. PubMed ID: 27283158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x
    Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD
    Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.
    Shahbandi A; Rao SG; Anderson AY; Frey WD; Olayiwola JO; Ungerleider NA; Jackson JG
    Cell Death Differ; 2020 Nov; 27(11):3097-3116. PubMed ID: 32457483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.